Global Muscle Relaxant Drugs Market

Muscle Relaxant Drugs Market Size, Share, Growth Analysis, By Type(Facial Muscle Relaxants, Skeletal Muscle Relaxants, and Neuromuscular Blocking Agents), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By End-user(Hospitals, Homecare, Specialty Clinics, and Others), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35I2316 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 91 | Figures: 76

Muscle Relaxant Drugs Market News

  • In March 2024, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP. This sterile solution is designed for intrathecal administration and serves as a muscle relaxant and antispastic.  
  • In November 2023, global pharmaceutical company Lupin announced the launch of Rocuronium Bromide Injection, the generic equivalent of Zemuron Injection, in the United States. It acts as a neuromuscular blocking agent, facilitating rapid sequence and routine tracheal intubation, and providing skeletal muscle relaxation during surgery or mechanical ventilation. 
  • In June 2023, Ahmedabad, India-based pharmaceutical company CORONA Remedies acquired the muscle relaxant brand Myoril from Sanofi India for INR 234 crore. The acquisition includes Myoril and its extensions. This acquisition comes after Corona's previous acquisitions of drug brands from GlaxoSmithKline and Abbott India.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Muscle Relaxant Market size was valued at USD 74 Billion in 2022 and is poised to grow from USD 102.12 Billion in 2023 to USD 1343.21 billion by 2031, at a CAGR of 38% during the forecast period (2024-2031).

In the domain of myorelaxant pharmaceuticals, a robust competition unfolds among medicinal enterprises. Diligently striving to conceive innovative and refined remedies for muscular afflictions, these corporations allocate substantial resources to exhaustive research endeavors. Their primary objective is to formulate medications that not only excel in effectiveness but also maintain a paramount standard of safety, thereby setting themselves apart within the market milieu. 'Amneal Pharmaceuticals LLC (US)', 'Ipsen Biopharmaceuticals, Inc. (US)', 'Merz Pharmaceuticals, LLC. (US)', 'Par Pharmaceutical (US)', 'Endo Pharmaceuticals (US)', 'Vertical Pharmaceuticals (US)', 'Mallinckrodt (US)', 'SteriMax (Canada)', 'Eisai Co., Ltd. (Japan)', 'Metacel Pharmaceuticals, LLC. (US)', 'Teva Pharmaceuticals USA, Inc. (US)', 'Sun Pharmaceutical Industries Ltd. (India)', 'Mylan Pharmaceuticals Inc. (US)', 'Dr. Reddy's Laboratories Ltd. (India)', 'Pfizer Inc. (US)', 'Novartis AG (Switzerland)', 'GlaxoSmithKline plc (UK)', 'Sanofi S.A. (France)', 'Aurobindo Pharma Ltd. (India)', 'AbbVie Inc. (US)'

One of the major key factors when it comes to the muscle relaxant drugs market is their increment in the population. As people start aging, they become more inclined towards muscle related conditions such as musculoskeletal disorders and muscle spas as well. The dependency and demand for these drugs has increased so much that nowadays it has become a daily habit for aging people to take it on a regular basis to avoid pain.

Increasing Preference for Non-Sedative Muscle Relaxants : In the domain of muscle relaxant pharmaceuticals, a prominent trend manifests in the escalating inclination towards muscle-relaxing substances that exhibit minimal sedative properties. Both patients and healthcare practitioners are progressively seeking remedies that alleviate muscular conditions without inducing excessive somnolence or functional impairment. This shift arises from the aspiration to uphold an elevated level of functionality and enhance the overall quality of life while proficiently addressing muscular concerns, especially in scenarios where heightened vigilance and productivity hold paramount significance. To meet the evolving preferences of patients, pharmaceutical enterprises are actively engaged in formulating and endorsing muscle relaxant medications characterized by enhanced safety profiles and diminished sedative impact, aligning with the burgeoning demand within this discerning patient demographic.

Amidst the realm of muscle relaxant medications, North America presently commands authority. This ascendancy stems from multifarious factors, encompassing a well-established healthcare framework, elevated healthcare disbursements, a substantial aging demographic grappling with muscular afflictions, and a robust pharmaceutical sector. Furthermore, the region's preeminence is fortified by the existence of pivotal market entities and their unwavering commitment to pioneering research and developmental endeavors.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Benzodiazepine Drugs Market
Buy Now GET FREE SAMPLE
Cardiovascular Drugs Market
Buy Now GET FREE SAMPLE
Local Anesthesia Drugs Market
Buy Now GET FREE SAMPLE
Active Pharmaceutical Ingredients (API) Market
Buy Now GET FREE SAMPLE
Narcolepsy Drugs Market
Buy Now GET FREE SAMPLE
Pain Management Therapeutics Market
Buy Now GET FREE SAMPLE
General Anesthesia Drugs Market
Buy Now GET FREE SAMPLE
Erectile Dysfunction Drugs Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Muscle Relaxant Drugs Market

Report ID: SQMIG35I2316

$5,300
BUY NOW GET FREE SAMPLE